Please visit answersincme.com/GDX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the clinical impact of approved and emerging combination treatments for advanced melanoma. Upon completion of this activity, participants should be better able to: Identify the unmet treatment needs for patients with advanced melanoma within the current therapeutic landscape; Recognize the mechanism of action of anti-lymphocyte activation gene-3 (anti-LAG-3) plus programmed cell death protein 1 (PD-1) combinations for the treatment of advanced melanoma; and Describe the clinical impact of approved and emerging anti-LAG-3 plus PD-1 combinations for the treatment of advanced melanoma.
View all episodes
